Target intelligence / Profile preview

DNA crosslinking adduct (or more specifically, “DNA interstrand crosslink” or “DNA-protein crosslink” depending on context)

Molecular classification
Other (structural DNA damage or modification; not a protein, receptor, enzyme, etc.)
01

Overview

DNA crosslinking/DNA adduct formation refers to chemical reactions in which DNA strands are covalently bonded either within the same strand (intrastrand), between strands (interstrand), or with proteins (DNA-protein crosslinks). These events typically arise following exposure to chemotherapeutic agents (alkylating agents, platinum compounds, mitomycin C, psoralens) or endogenous reactive molecules. DNA crosslinking blocks critical processes such as DNA replication and transcription, thereby triggering cell cycle arrest and cell death. Unrepaired crosslinks are highly cytotoxic and underlie the efficacy of many cancer drugs, but also contribute to side effects such as bone marrow toxicity and secondary cancer development. DNA crosslink damage is repaired by specialized cellular pathways, notably the Fanconi anemia pathway for interstrand crosslinks and SPRTN/proteasome pathway for DNA-protein crosslinks.

Other names
DNA adductDNA interstrand crosslinkDNA-protein crosslinkDNA lesionDNA modification
02

Mechanism of action

Covalent modification of DNA bases leading to interstrand or intrastrand crosslinks, or DNA-protein adducts; blocks DNA replication and transcription, drives apoptosis or senescence

03

Biological functions

DNA damage responseGenome instability inductionCell death (apoptosis, necrosis)Blockade to DNA replication and transcription
04

Disease associations

Cancer (as a therapeutic target for cell killing by drugs)Genetic disease (mutations in DNA crosslink repair proteins cause syndromes like Fanconi anemia, Ruijs-Aalfs syndrome, karyomegalic interstitial nephritis)
05

Safety considerations

Off-target toxicity (bone marrow suppression, secondary malignancies)Genome instabilityMutagenesis and carcinogenic riskOrgan toxicities linked to specific agents (e.g. nephrotoxicity by cisplatin)
06

Interacting drugs

Alkylating agents (e.g. cyclophosphamide, ifosfamide, melphalan, chlorambucil)

3 more in the full profile.

07

Biomarkers

DNA adduct quantification (biomarker of drug exposure/effect)Fanconi anemia protein expression (repair proficiency)SPRTN, BRCA1, WRN levels (repair genes for DNA crosslink damage)

Beyond the preview

Go deeper on DNA crosslinking adduct (or more specifically, “DNA interstrand crosslink” or “DNA-protein crosslink” depending on context).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA crosslinking adduct (or more specifically, “DNA interstrand crosslink” or “DNA-protein crosslink” depending on context).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call